In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.
The comparative in vitro potency of XRP2868, a new oral semisynthetic streptogramin antibiotic, was evaluated against gram-positive bacteria. XRP2868 inhibited all staphylococci at < or = 1 microg/ml and all non-pneumococcal streptococci at < or = 0.25 microg/ml and was fourfold more potent than quinupristin-dalfopristin against Staphylococcus aureus and Enterococcus faecium.
Eliopoulos
G M
GM
Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA. geliopou@bidmc.harvard.edu
Ferraro
M J
MJ
Wennersten
C B
CB
Moellering
R C
RC
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D025361:Streptogramins / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D025361:Streptogramins